Targeting epigenetic modifiers: Inhibitors of histone methyltransferases

被引:35
作者
Bissinger, Elisabeth-Maria [1 ]
Heinke, Ralf [2 ]
Sippl, Wolfgang [2 ]
Jung, Manfred [1 ]
机构
[1] Univ Freiburg, Inst Pharmaceut Sci, D-79104 Freiburg, Germany
[2] Univ Halle Wittenberg, Dept Pharmaceut Chem, D-06120 Halle, Germany
关键词
PROTEIN ARGININE METHYLATION; TUMOR-SUPPRESSOR GENES; LYSINE-METHYLTRANSFERASES; IN-VIVO; CHROMATIN MODIFICATIONS; EXPRESSION; COACTIVATOR; DNA; CANCER; DEMETHYLATION;
D O I
10.1039/c0md00062k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The term epigenetics is defined as Inheritable changes that influence the outcome of a phenotype without changes in the genome Epigenetics is based upon DNA methylation and posttranslational histone modifications While there is much known about reversible acetylation as a posttranslational modification, research on histone methylation is still emerging, especially with regard to drug discovery As aberrant epigenetic modifications have been linked to many diseases, inhibitors of histone methylation are very much in demand This article gives an outline on the different histone methyltransferases, their involvement in disease, the available inhibitors and their potential as drugs
引用
收藏
页码:114 / 124
页数:11
相关论文
共 107 条
[1]   UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development [J].
Agger, Karl ;
Cloos, Paul A. C. ;
Christensen, Jesper ;
Pasini, Diego ;
Rose, Simon ;
Rappsilber, Juri ;
Issaeva, Irina ;
Canaani, Eli ;
Salcini, Anna Elisabetta ;
Helin, Kristian .
NATURE, 2007, 449 (7163) :731-U10
[2]   New nomenclature for chromatin-modifying enzymes [J].
Allis, C. David ;
Berger, Shelley L. ;
Cote, Jacques ;
Dent, Sharon ;
Jenuwien, Thomas ;
Kouzarides, Tony ;
Pillus, Lorraine ;
Reinberg, Danny ;
Shi, Yang ;
Shiekhattar, Ramin ;
Shilatifard, Ali ;
Workman, Jerry ;
Zhang, Yi .
CELL, 2007, 131 (04) :633-636
[3]  
Aniello F, 2006, ANTICANCER RES, V26, P2063
[4]   EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast [J].
Bachmann, IM ;
Halvorsen, OJ ;
Collett, K ;
Stefansson, IM ;
Straume, O ;
Haukaas, SA ;
Salvesen, HB ;
Otte, AP ;
Akslen, LA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) :268-273
[5]   Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription [J].
Balasubramanyam, K ;
Varier, RA ;
Altaf, M ;
Swaminathan, V ;
Siddappa, NB ;
Ranga, U ;
Kundu, TK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (49) :51163-51171
[6]   Arginine methylation at a glance [J].
Bedford, Mark T. .
JOURNAL OF CELL SCIENCE, 2007, 120 (24) :4243-4246
[7]   Arginine methylation: An emerging regulator of protein function [J].
Bedford, MT ;
Richard, S .
MOLECULAR CELL, 2005, 18 (03) :263-272
[8]   CD28 costimulatory signal induces protein arginine methylation in T cells [J].
Blanchet, F ;
Cardona, A ;
Letimier, FA ;
Hershfield, MS ;
Acuto, O .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (03) :371-377
[9]   Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control [J].
Boisvert, FM ;
Déry, U ;
Masson, JY ;
Richard, S .
GENES & DEVELOPMENT, 2005, 19 (06) :671-676
[10]  
BOISVERT FM, 2005, SCI STKE, pRE2, DOI DOI 10.1126/STKE.2712005RE2